Biotech investment intelligence

Biotech catalysts, clearly tracked.

Upcoming trial readouts, clinical pipelines and FDA milestones across a growing universe of biotech companies — updated daily from public data.

View catalyst calendar Browse companies

Next catalysts

All →
Upcoming readouts
BEAM2026-12BEAM2026-12CRSP2027-06CRSP2027-06VRTX2027-06VRTX2027-06NTLA2027-07VRTX2027-07
ExpectedCompanyPhaseIndication
2026-12 BEAM Unspecified Sickle Cell Trait
2026-12 BEAM Phase 1/2 Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
2027-06 CRSP Phase 1 Cardiovascular, Metabolic Disease, Dyslipidemias
2027-06-06 CRSP Phase 3 Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance
2027-06-09 VRTX Phase 3 Beta-Thalassemia, Thalassemia, Hematologic Diseases
2027-06-30 VRTX Phase 3 Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
2027-07 NTLA Phase 3 Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease
2027-07-22 VRTX Phase 2 Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Tracked companies

All →
CRSP CRISPR Therapeutics 8 trials NTLA Intellia Therapeutics 7 trials BEAM Beam Therapeutics 8 trials MRNA Moderna 1 trials VRTX Vertex Pharmaceuticals 12 trials

Pipeline snapshot

Full pipeline →
Trials by phase
Phase 311Phase 1/29Unspecified5Phase 14Phase 23Phase 2/32Phase 42
11Phase 3
9Phase 1/2
5Unspecified
4Phase 1
3Phase 2
2Phase 2/3
2Phase 4